Auris Medical
Cochlear therapies

Innovative Treatments in Neurotology and Mental Health Supportive Care

Strategy & Business Update
Third Quarter 2018 Financial Results

November 15, 2018

NASDAQ: EARS

Forward-looking Statements

This presentation and the accompanying oral commentary may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the ability to pursue strategic partnering and non-dilutive funding for its Phase 3 programs, the timing and conduct of clinical trials of Auris Medical’s product candidates, the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2017, and in Auris Medical's other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Key Highlights

Clinical Highlights

- Reported positive outcomes from second Phase 1 trial with intranasal betahistine
  - ➢Provided further evidence for betahistine's preventive effects in antipsychotic-induced weight gain
  - ➢Progressing intranasal betahistine program towards proof-of-concept studies

Partnering Highlights

- Initiated partnering process for AM-111 program

Commercial Highlights

- Announced acceptance of Sonsuvi® as brand name for AM-111



Intranasal Betahistine Program Update

Auris Medical
Cochlear therapies

Superior Bioavailability Confirmed



- Relative bioavailability of intranasal betahistine in blood plasma vs. oral betahistine 48 mg
  - 6-29 x (p values 0.056 to <0.0001)
- Overall, good safety profile confirmed; transient, dose-dependent nasal tolerability signals as expected
- Maximum tolerated dose with repeated dosing (3 x daily for 3 days): 40 mg
- Safety package ready for requesting approvals for one-month studies



Project AM-125 Update

Auris Medical
Cochlear therapies

Planning for Phase 2 Trial



Expect to initiate Phase 2 trial with AM-125 (TRAVERS) in Q1 2019

Trial Details

- Patients with loss of vestibular function following vestibular schwannoma resection
- Model endorsed by EMA for proof-of-concept through Scientific Advice
- To be conducted in several European countries and potentially, Canada
  - Site selection ongoing:12-15 sites
- Initiation planned for Q1 2019
- Target enrollment = 138 patients
- Primary objective = accelerate and improve vestibular recovery

Design of TRAVERS Phase 2 Trial

Auris Medical
Cochlear therapies

Part A
N = 50 + 16

- Dose Escalation: 5 steps with AM-125 vs. placebo (t.i.d.)
- Open-label oral betahistine (48 mg)
- Primary Efficacy Endpoints: time standing on foam, tandem Romberg test

Interim Analysis

- Determine dose response curve
- Pick two doses for Part B
- Re-assess sample size and powering assumptions for Part B

Part B
N = [72]

- Assess AM-125 high dose and low dose against placebo



Project AM-201 Update

Auris Medical
Cochlear therapies

Planning for Proof-Of-Concept Study

Auris Medical
Cochlear therapies

Expect to initiate pharmacokinetic/pharmacodynamic (PK/PD) trial with AM-201 in first quarter of 2019

Trial Details

- 50 healthy volunteers
- Single European site
- Olanzapine treatment + AM-201 or placebo over four weeks
- Start planned for Q1 2019

Trial Objectives

- Primary objective = reduction in weight gain
- Secondary objective = reduction in daytime sleepiness
- Test potential interaction olanzapine / betahistine

Design of PK/PD Trial

Screening

- Healthy male or female volunteers 18-50 years of age
- BMI 18-25 kg/m^2
- **Dose escalation:** 5 steps with AM-201 vs. placebo (t.i.d.)

Titration OLZ

- Titrate OLZ up to 10 mg (7.5 mg) q.d. within first week
- Subjects who do not tolerate OLZ or who gain clinically relevant amount of weight or high glucose level to be replaced

Maintenance

- Maintain OLZ dose for three weeks

Further Data On Betahistine's Preventive Effects

Auris Medical
Cochlear therapies



- Recent publication providing further evidence for betahistine's preventive effects on antipsychotic-induced weight gain
- Oral betahistine 36-48 mg per day or placebo over 12 weeks
- 51 adolescent and adult patients who received at the same time various antipsychotic drugs
- In sub-group of patients treated with olanzapine or clozapine (n=26), betahistine was significantly better than placebo in preventing increases in:
  - weight (3.1 kg less weight gain than placebo)
  - body mass index
  - waist circumference

Smith RC et al. (2018). Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology (Berl), in press.

Project AM-111 Update

Auris Medical
Cochlear therapies

Introducing Sonsuvi®

- Target indication = treatment of acute sensorineural hearing loss
  - Orphan Drug Designation, Fast Track
- Sonsuvi® (“son-SUE-vee”) conditionally approved by FDA as brand name for AM-111
- Follows previous endorsement by EMA
- Subject to final review at the time of marketing approval
- Registered as trademark in various countries
- FDA guidance on AM-111 development program through type C meeting
- FDA endorsed
  - proposed choice of primary and secondary efficacy endpoints
  - the safety endpoints
  - planned sample size
  - statistical methodology

Partnering Process Initiated

- Refocus development activities on intranasal betahistine program
- Seek partners or other sources of non-dilutive funding for late-stage development programs
- Mandated JSB Partners, Boston, an international transaction advisory firm
  - Identify potential partners for AM-111 development program
  - Provide support for partnering discussions and negotiations
- Process started
- “First-in-class” drug for treating acute inner ear hearing loss



Financial Update

Auris Medical
Cochlear therapies

Third Quarter 2018 Financial Update

CHF	Q3 2018	Q3 2017
Net Income (Loss)	(3.0 million)	(6.0 million)
EPS	(0.14)	(1.36)
R&D Expenses	1.7 million	4.2 million
General & Administrative Expenses	1.2 million	1.3 million

Operating Expenses 2018 (Guidance)

- CHF 10 to 12.9 million

Cash Position

- Cash and cash equivalents (at September 30, 2018) totaled CHF 5.3 million
- Cash runway into second quarter of 2019
- Exercise of warrants from the July 2018 offering as well as the sale of shares under the equity line with LPC since end of Q3 have increased cash and cash equivalents by approximately CHF 2.7 million.



Outlook and Conclusions

Auris Medical
Cochlear therapies

Upcoming Milestones





Take care of your ears!

Auris Medical Holding AG
Bahnhofstrasse 21
CH-6300 Zug
Tel. +41 41 729 71 94 | Fax +41 61 201 13 51
www.aurismedical.com | NASDAQ: EARS

Auris Medical
Cochlear therapies